Abstract
PurposeHearing impairment has a great impact on children's auditory language development, which causes serious socio-economic burden. Existing data showed the effect of antenatal dexamethasone treatment on hearing of premature infants is controversial, which may be caused by different treatment courses. Therefore, this study explored the effects of different courses of antenatal dexamethasone treatment on hearing of premature infants. MethodAll premature infants born in West China Second University Hospital, Sichuan University from 2018 to 2020 with abnormal hearing screening were included. We matched premature infants who passed the hearing screening according to the gestational age (±1 week) at a ratio of 1:1. Antenatal dexamethasone information, hearing screening results, and postnatal diagnosis related to hearing were available. ResultsA total of 299 premature infants failed hearing screening. In the final logistic model, antenatal use of 4 doses of dexamethasone reduced the hearing screening failure rate of premature infants (OR 0.39; 95 % CI: 0.22–0.69). Excessive exposure (OR 1.01; 95 % CI: 0.45–2.23) and incomplete exposure (OR 1.03; 95 % CI: 0.59–1.80) had no effect on the hearing screening of premature infants. ConclusionAntenatal dexamethasone therapy has a dose-dependent protective effect on hearing loss in premature infants.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Otolaryngology--Head and Neck Medicine and Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
